4-aminobenzoic acid has been researched along with abt-199 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Birzele, F; Dangl, M; Friess, T; Kiialainen, A; Lehmann, C | 1 |
| Friess, T; Herting, F; Klein, C; Middleton, S; Umaña, P | 1 |
| Andreeff, M; Konopleva, M; Leverson, JD; Mu, H; Nichols, G; Pan, R; Reed, JC; Ruvolo, V | 1 |
| Chang, Y; Ding, K; Guo, H; Hao, P; Li, L; Li, Z; Ni, Y; Xu, Y; Zhang, ZM; Zhu, D | 1 |
| Abdeldayem, A; Aittokallio, T; Bhatti, MN; Bukhari, S; de Araujo, ED; Gawel, JM; Geletu, M; Gunning, PT; Hassan, MM; Herling, M; Ianevski, A; Israelian, J; Krämer, OH; Manaswiyoungkul, P; Moriggl, R; Mustjoki, S; Nawar, N; Neubauer, HA; Olaoye, OO; Radu, TB; Raouf, YS; Sedighi, A; Shouksmith, AE; Sorger, H; Timonen, S; Toutah, K; von Jan, J | 1 |
5 other study(ies) available for 4-aminobenzoic acid and abt-199
| Article | Year |
|---|---|
Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Synergism; Female; Gene Expression Profiling; Heterografts; Humans; Leukemia, Myeloid, Acute; Mice; Myeloid Cell Leukemia Sequence 1 Protein; para-Aminobenzoates; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Sequence Analysis, RNA; Sulfonamides; Tumor Suppressor Protein p53 | 2016 |
Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma.
Topics: Animals; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Drug Therapy, Combination; Humans; Lymphoma, Non-Hodgkin; Mice; para-Aminobenzoates; Pyrrolidines; Sulfonamides; Xenograft Model Antitumor Assays | 2018 |
Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; para-Aminobenzoates; Proto-Oncogene Proteins c-bcl-2; Pyrrolidines; Sulfonamides; Synthetic Lethal Mutations; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2017 |
Cell- and Tissue-Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fluorescent Dyes; Humans; MCF-7 Cells; Models, Molecular; Molecular Structure; Optical Imaging; para-Aminobenzoates; Proteome; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Structure-Activity Relationship; Sulfonamides | 2018 |
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Prolymphocytic, T-Cell; Male; Mice; Molecular Docking Simulation; Molecular Structure; para-Aminobenzoates; Pyrrolidines; Structure-Activity Relationship; Sulfonamides | 2021 |